AMGN•benzinga•
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Summary
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga